Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02480010 | A Study of Pertuzumab in Participants With Prostate Cancer | terminated | Phase 2 | 68 | Hoffmann-La RocheINDUSTRY | 6 | Sep 18, 2015 | clinicaltrials |
| NCT01808534 | Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors | terminated | Phase 2 | 5 | Indiana UniversityOTHER | 1 | Jul 2, 2015 | clinicaltrials |
| NCT01705652 |
| Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients(Nexrutine) |
| terminated |
| Phase 2 |
| 21 |
| The University of Texas Health Science Center at San AntonioOTHER |
| 1 |
| Jun 11, 2015 |
| clinicaltrials |
| NCT00118066 | Calcitriol in Preventing Prostate Cancer in Patients With Prostatic Intraepithelial Neoplasia | terminated | Phase 2 | 12 | Rutgers, The State University of New JerseyOTHER | 1 | May 27, 2015 | clinicaltrials |
| NCT00176293 | Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer | terminated | Phase 2 | 2 | University of KentuckyOTHER | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00217464 | Fulvestrant in Treating Patients With Recurrent Prostate Cancer | terminated | Phase 2 | 17 | Roswell Park Cancer InstituteOTHER | 1 | Apr 16, 2015 | clinicaltrials |
| NCT01267266 | Saracatinib in Treating Patients With Prostate Cancer | terminated | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Apr 1, 2015 | clinicaltrials |
| NCT00058214 | Perifosine in Treating Patients With Recurrent Prostate Cancer | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2015 | clinicaltrials |
| NCT00539968 | A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) | terminated | Phase 1 / Phase 2 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 5, 2015 | clinicaltrials |
| NCT01469338 | Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel | terminated | Phase 2 | 9 | University of Southern CaliforniaOTHER | 1 | Nov 24, 2014 | clinicaltrials |
| NCT01531205 | Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA | terminated | Phase 2 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 5, 2014 | clinicaltrials |
| NCT00753220 | Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer(CRITICAL) | terminated | Phase 1 / Phase 2 | 7 | Bostwick LaboratoriesINDUSTRY | 1 | Nov 4, 2014 | clinicaltrials |
| NCT00918385 | Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer(ARS) | terminated | Phase 2 | 57 | Duke UniversityOTHER | 1 | Oct 29, 2014 | clinicaltrials |
| NCT01020305 | Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 5 | Sandy SrinivasOTHER | 1 | Oct 13, 2014 | clinicaltrials |
| NCT01704027 | Safety Study of Pelvic and Prostatic SIB-IMRT With Long-term Androgen Deprivation for High Risk Localized Prostate Cancer | terminated | Phase 2 | 28 | Centre Georges Francois LeclercOTHER | 1 | Sep 18, 2014 | clinicaltrials |
| NCT00385827 | A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC) | terminated | Phase 2 | 106 | Centocor, Inc.INDUSTRY | 7 | Aug 20, 2014 | clinicaltrials |
| NCT00004050 | Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer | terminated | Phase 2 | 13 | VicalINDUSTRY | 1 | Jul 29, 2014 | clinicaltrials |
| NCT00005072 | Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer | terminated | Phase 1 / Phase 2 | 25 | VicalINDUSTRY | 1 | Jul 29, 2014 | clinicaltrials |
| NCT00515112 | Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer | terminated | Phase 2 | 6 | University of ChicagoOTHER | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00593853 | Efficacy Study of Methylphenidate Hydrochloride to Reduce Fatigue in Prostate Cancer Patients Receiving Hormone Therapy | terminated | Phase 2 | 33 | University Health Network, TorontoOTHER | 1 | Jun 4, 2014 | clinicaltrials |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT01483586 | Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer | terminated | Phase 2 | 90 | KangLaiTe USAINDUSTRY | 1 | Apr 14, 2014 | clinicaltrials |
| NCT00678015 | Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer | terminated | Phase 2 | 12 | University of California, San FranciscoOTHER | 1 | Apr 9, 2014 | clinicaltrials |
| NCT00887640 | Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer | terminated | Phase 2 | 11 | Duke UniversityOTHER | 1 | Feb 26, 2014 | clinicaltrials |
| NCT01176513 | GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer | terminated | Phase 2 | 25 | GE HealthcareINDUSTRY | 1 | Feb 14, 2014 | clinicaltrials |
| NCT00479635 | A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer | terminated | Phase 2 | 26 | Cortice Biosciences, Inc.INDUSTRY | 1 | Jan 22, 2014 | clinicaltrials |
| NCT01000948 | A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer(DAPROCA-1) | terminated | Phase 2 | 24 | Aarhus University HospitalOTHER | 1 | Jan 8, 2014 | clinicaltrials |
| NCT00917865 | FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer | terminated | Phase 2 | 11 | David M. Schuster, MDOTHER | 1 | Jan 7, 2014 | clinicaltrials |
| NCT00510224 | Sandostatin for Patients With Androgen Independent Prostate Cancer | terminated | Phase 2 | 13 | University of California, San FranciscoOTHER | 1 | Dec 11, 2013 | clinicaltrials |
| NCT00945477 | Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade | terminated | Phase 2 | 11 | Illinois CancerCare, P.C.OTHER | 1 | Nov 18, 2013 | clinicaltrials |
| NCT00814892 | Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer | terminated | Phase 2 | 2 | Mayo ClinicOTHER | 1 | Nov 5, 2013 | clinicaltrials |
| NCT00332280 | Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo | terminated | Phase 2 / Phase 3 | 67 | Auron Healthcare GmbHINDUSTRY | 2 | Mar 20, 2013 | clinicaltrials |
| NCT00383487 | A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer | terminated | Phase 2 | 20 | Stanford UniversityOTHER | 1 | Jan 28, 2013 | clinicaltrials |
| NCT00005039 | Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer) | terminated | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00042952 | Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer | terminated | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00714376 | Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients(TAX1) | terminated | Phase 2 | 6 | CHU de Quebec-Universite LavalOTHER | 1 | Oct 31, 2012 | clinicaltrials |
| NCT00293371 | Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 6 | University of California, San FranciscoOTHER | 1 | Oct 11, 2012 | clinicaltrials |
| NCT00006371 | A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer | terminated | Phase 2 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 27, 2012 | clinicaltrials |
| NCT00058266 | Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy | terminated | Phase 2 | 36 | Northwestern UniversityOTHER | 1 | Jul 19, 2012 | clinicaltrials |
| NCT00471718 | ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | terminated | Phase 1 / Phase 2 | 27 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jul 11, 2012 | clinicaltrials |
| NCT00127387 | Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia | terminated | Phase 2 / Phase 3 | 54 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jun 26, 2012 | clinicaltrials |
| NCT00881725 | A Study of Pre-operative Metformin in Prostate Cancer(ANIMATE) | terminated | Phase 2 | 24 | University Health Network, TorontoOTHER | 1 | Jun 19, 2012 | clinicaltrials |
| NCT00048659 | YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy | terminated | Phase 2 | — | Astellas Pharma IncINDUSTRY | 10 | Jun 7, 2012 | clinicaltrials |
| NCT00050297 | YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer | terminated | Phase 2 | — | Astellas Pharma IncINDUSTRY | 7 | Jun 7, 2012 | clinicaltrials |
| NCT00073970 | Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy | terminated | Phase 2 | 37 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 23, 2012 | clinicaltrials |
| NCT01340599 | Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery | terminated | Phase 2 | 5 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 15, 2012 | clinicaltrials |
| NCT01132404 | Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448 | terminated | Phase 1 / Phase 2 | 9 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 31, 2012 | clinicaltrials |
| NCT00452387 | Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC) | terminated | Phase 2 | 22 | Accelerated Community Oncology Research NetworkOTHER | 1 | Sep 16, 2011 | clinicaltrials |
| NCT00117312 | Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients | terminated | Phase 2 | 37 | Ferring PharmaceuticalsINDUSTRY | 1 | May 23, 2011 | clinicaltrials |
| NCT00215657 | Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients | terminated | Phase 2 | 131 | Ferring PharmaceuticalsINDUSTRY | 0 | May 20, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Sep 18, 2015source: clinicaltrials